Visirna Therapeutics
↗Shanghai, China
Visirna Therapeutics is a China-based, clinical-stage biopharmaceutical company focused on the development and commercialization of innovative siRNA (small interfering RNA) therapeutics. Founded in 2022 as a joint venture between Arrowhead Pharmaceuticals and Vivo Capital, the company aims to address significant unmet medical needs in cardiometabolic, hematology, and nephrology diseases within the Greater China market.
Visirna leverages a proprietary oligonucleotide platform and maintains a strategic partnership with Arrowhead Pharmaceuticals, which provides access to a pipeline of investigational RNAi candidates. The company has established comprehensive capabilities spanning clinical development, regulatory strategy, and commercialization, positioning itself as a key player in the Chinese RNAi therapeutic landscape.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2022
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$60M
Investors:Vivo Capital, Arrowhead Pharmaceuticals
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3 (Plozasiran)
Modalities:RNA, siRNA
Active Trials:8
Trial Phases:Phase 1: 1 | Phase 2: 1 | Phase 3: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Arrowhead Pharmaceuticals (Strategic partner/licensor), Sanofi (Commercialization partner for Plozasiran in Greater China)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Dong You - EVP
LINKS
Website:visirna.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Visirna Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Visirna Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.